Advertisement
Advertisement
U.S. markets close in 2 hours 4 minutes
Advertisement
Advertisement
Advertisement
Advertisement

China Pharma Holdings, Inc. (CPHI)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.4136-0.0204 (-4.70%)
As of 01:53PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close0.4340
Open0.4643
Bid0.4061 x 800
Ask0.4210 x 1200
Day's Range0.4050 - 0.4340
52 Week Range0.3800 - 1.6300
Volume60,974
Avg. Volume1,053,035
Market Cap19.58M
Beta (5Y Monthly)0.17
PE Ratio (TTM)N/A
EPS (TTM)-0.0800
Earnings DateMay 14, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CPHI

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • China Pharma Holdings, Inc.
    Weekly Stock ListThis is among our most-important themes for 2022, and stretches across industries. We think companies that raise their dividends consistently at a double-digit rate are sending off three important signals amid all the recent market volatility: 1) the company's balance sheet is strong enough to pay a dividend; 2) management is focused on providing shareholder returns; and 3) management is confident enough in the near-term outlook to raise the payout aggressively. This third factor is especially important as the pandemic upends the nation's recent record of long-term economic growth. Here are 12 stocks that meet our double-digit dividend test and are on the Argus BUY list. They are also holdings in our Dividend Growth Separately Managed Account and in the Dividend Growers Total Return Trust, sponsored by SmartTrust.
    Rating
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • PR Newswire

    China Pharma Holdings, Inc. Reports Third Quarter 2021 Financial Results

    China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the financial results for the quarter ended September 30, 2021.

  • PR Newswire

    China Pharma Holdings, Inc. Reports Second Quarter 2021 Financial Results

    China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the financial results for the quarter ended June 30, 2021.

  • PR Newswire

    China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval

    China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its Candesartan hypertension product passed key bioequivalence tests. The Company plans to use the results of the key benchmark tests of consistency evaluation to apply for the National Medical Products Administration's (NMPA) approval. The NMPA is the Chinese agency for regulating drugs and medical devices (formerly the China Food and Drug Administr

Advertisement
Advertisement